Riken Vitamin Co., Ltd.
Notice Regarding the Status of Treasury Stock Acquisition (Based on Provisions of Article 165, Paragraph 2 of the Companies Act)
Acquired 62,200 shares of treasury stock totaling 190,219,693 yen from January 1 to January 31, 2026. The cumulative number of shares acquired is 585,900, with a total acquisition cost of 1,664,751,327 yen.
Key Figures
- Total number of shares acquired (January 1, 2026 – January 31, 2026): 62,200 shares
- Total acquisition cost (January 1, 2026 – January 31, 2026): 190,219,693 yen
- Cumulative treasury stock acquisition (as of January 31, 2026): 585,900 shares, 1,664,751,327 yen
AI要約
Overview of Treasury Stock Acquisition
Riken Vitamin Co., Ltd. has been conducting treasury stock acquisitions based on the Board of Directors resolution dated April 30, 2025, pursuant to the provisions of Article 165, Paragraph 3 of the Companies Act. During the period from January 1 to January 31, 2026, the company acquired 62,200 shares of its common stock through market purchases on the Tokyo Stock Exchange, totaling 190,219,693 yen. The cumulative total stands at 585,900 shares, with a total acquisition cost of 1,664,751,327 yen. The target shares are our common stock, with an acquisition limit of 1,000,000 shares and an acquisition price limit of 2,000,000,000 yen.
Impact on Shareholders and Future Outlook
This treasury stock acquisition has an upper limit of 3.34% of the total number of issued shares and aims to enhance shareholder value and improve capital efficiency. Acquisitions are conducted via market purchases, and acquisitions up to the upper limit may continue until March 24, 2026. This is expected to improve earnings per share and strengthen shareholder returns, although specific dilution rate changes and details of fund usage are not disclosed.
